Originally published as JCO Early Release 10.1200/JCO.2008.16.1513 on March 9 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luigi Zinzani, P. Articles by Baccarani, M. Search for Related Content PubMed PubMed Citation Articles by Luigi Zinzani, P. Articles by Baccarani, M. Related Articles Related Article Related Editorial Social Bookmarking                            What's this?

Role of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

From the Institute of Hematology and Medical Oncology "L. & A. Seràgnoli," University of Bologna; and Department of Nuclear Medicine, S. Orsola-Malpighi Hospital, Bologna, Italy.

Corresponding author: Pier Luigi Zinzani, MD, Institute of Hematology and Oncology "L. & A. Seràgnoli," Via Massarenti 9, 40138 Bologna Italy; e-mail: plzinzo{at}med.unibo.it.

Purpose In lymphoma, [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification of disease relapse. However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission.

Patients and Methods All patients with lymphoma who achieved the first complete remission were prospectively enrolled onto the study and scheduled for serial FDG-PET scans at 6, 12, 18, and 24 months; further scans were then carried out on an annual basis. Overall, the population included 421 patients (160 patients with Hodgkin's lymphoma [HL], 183 patients with aggressive non-Hodgkin's lymphoma [NHL], and 78 patients with indolent follicular NHL). All patients had a regular follow-up evaluation, including complete clinical and laboratory evaluation, and final assessment of any suspect FDG-PET findings using other imaging procedures (computed tomography [CT] scan) and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive for relapse, inconclusive (when equivocal), or negative for relapse.

Results PET enabled documentation of lymphoma relapse in 41 cases at 6 months, in 30 cases at 12 months, in 26 cases at 18 months, in 10 cases at 24 months, and in 11 cases at more than 36 months. All 36 patients with inconclusive positive PET underwent biopsy; only 12 (33%) of 36 patients had a concomitant suggestion of positivity on CT. A lymphoma relapse was diagnosed in 24 (66%) of 36 patients.

Conclusion Our results confirm FDG-PET as a valid tool for follow-up of patients with HL and NHL. In patients with inconclusive positive results, histologic confirmation plays an important role in identifying true relapse.

Supported in part by BolognAIL.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
  Teruhiko Terasawa, Joseph Lau, Stéphane Bardet, Olivier Couturier, Tomomitsu Hotta, Martin Hutchings, Takashi Nihashi, and Hirokazu Nagai
  JCO 2009 27: 1906-1914 [Abstract] [Full Text]

Related Editorial

• The Case Against Heavy PETing
  Bruce Cheson
  JCO 2009 27: 1742-1743 [Full Text]

This article has been cited by other articles:

				U. Petrausch, P. Samaras, P. Veit-Haibach, A. Tschopp, J. D. Soyka, A. Knuth, T. F. Hany, A. Mischo, C. Renner, and N. G. Schaefer Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann. Onc., November 13, 2009; (2009) mdp519v1. [Abstract] [Full Text] [PDF]

				H. Mocikova, P. Obrtlikova, B. Vackova, and M. Trneny Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study Ann. Onc., November 9, 2009; (2009) mdp522v1. [Abstract] [Full Text] [PDF]

				Lymphoma Follow-Up Using PET Imaging Journal Watch Oncology and Hematology, May 5, 2009; 2009(505): 2 - 2. [Full Text]

				B. Cheson The Case Against Heavy PETing J. Clin. Oncol., April 10, 2009; 27(11): 1742 - 1743. [Full Text] [PDF]